91桃色视频

January 22, 2024: 91桃色视频: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Date : January 22, 2024

91桃色视频: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Lyon, France, January 22nd, 2024 – 6:00 pm CET 鈥� 91桃色视频 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity agreement entrusted by 91桃色视频 to Kepler Cheuvreux, the following resources were listed on the liquidity account on December 31st, 2023:

  • 24,236 shares
  • 鈧� 34,107.60
  • Number of executions on buy side on semester: 627
  • Number of executions on sell side on semester: 368
  • Traded volume on buy side on semester: 18,328 shares for 鈧� 122,340.49
  • Traded volume on sell side on semester: 9,576 shares for 鈧� 64,693.03

As a reminder:

  • the following resources appeared on the last half year statement on June 30, 2023 on the liquidity account:
    • 15,484 shares
    • 鈧� 41,285.13
  • Number of executions on buy side on semester: 552
  • Number of executions on sell side on semester: 431
  • Traded volume on buy side on semester: 15,974 shares for 鈧� 144,745.75
  • Traded volume on sell side on semester: 12,997 shares for 鈧� 122,384.16

The following resources appeared on the liquidity account when the activity started:

  • 0 shares
  • 鈧� 200,000.00

The liquidity contract has been in effect since March 14, 2022, in accordance with the authorization granted by the General Meeting on March 3, 2022, and renewed on June 19, 2023. The implementation of this report is carried out in accordance with AMF Decision N掳2021-01 of June 22, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

Buy side Sell side
Number of executions Number of shares Traded volume in EUR Number of executions Number of shares Traded volume in EUR
Total 627 18 328 122 340,49 368 9 576 64 693,03
03/07/2023 5 447 3 111,12 – – –
04/07/2023 21 845 5 391,10 – – –
05/07/2023 4 284 1 848,84 1 1 6,90
06/07/2023 4 111 747,03 1 1 6,84
07/07/2023 3 70 466,20 – – –
10/07/2023 – – – 1 50 335,00
12/07/2023 1 30 201,00 – – –
13/07/2023 3 20 133,00 – – –
14/07/2023 1 1 6,62 1 1 6,62
17/07/2023 3 110 715,00 – – –
18/07/2023 3 100 640,00 – – –
19/07/2023 1 20 128,00 2 40 258,40
20/07/2023 1 40 256,00 1 50 323,00
21/07/2023 1 40 256,00 – – –
24/07/2023 – – – 1 30 192,60
25/07/2023 2 21 134,40 1 1 6,40
26/07/2023 2 51 325,38 1 1 6,38
27/07/2023 1 50 320,00 4 66 423,72
28/07/2023 3 100 633,00 2 54 345,60
31/07/2023 3 100 621,00 3 71 454,40
01/08/2023 1 50 320,00 4 129 833,34
02/08/2023 2 80 508,00 – – –
03/08/2023 – – – 3 50 320,00
04/08/2023 5 31 195,30 1 1 6,30
07/08/2023 – – – 1 20 128,00
08/08/2023 1 20 128,00 – – –
09/08/2023 2 24 152,16 – – –
10/08/2023 1 1 6,38 1 1 6,38
11/08/2023 1 1 6,38 2 7 44,80
14/08/2023 4 50 315,00 – – –
15/08/2023 1 1 6,32 2 31 198,40
16/08/2023 3 31 195,30 1 1 6,38
17/08/2023 1 10 63,00 1 20 128,00
18/08/2023 2 21 132,30 1 1 6,38
21/08/2023 – – – 2 50 320,00
22/08/2023 2 41 258,30 1 1 6,38
23/08/2023 3 30 188,70 2 60 382,20
24/08/2023 3 30 189,00 1 20 128,00
25/08/2023 6 116 709,92 5 94 579,98
28/08/2023 5 90 547,20 2 11 69,30
29/08/2023 4 31 192,20 3 48 304,32
30/08/2023 6 370 2 353,20 – – –
31/08/2023 5 109 683,43 – – –
05/09/2023 1 1 6,30 1 1 6,30
06/09/2023 1 1 6,32 1 1 6,32
07/09/2023 7 248 1 550,00 3 150 969,00
08/09/2023 5 244 1 520,12 2 151 966,40
11/09/2023 2 6 38,04 – – –
12/09/2023 7 344 2 132,80 4 100 626,00
13/09/2023 2 31 195,30 5 81 515,16
14/09/2023 1 20 126,00 1 20 128,00
18/09/2023 4 151 943,75 3 80 500,80
19/09/2023 5 60 369,00 2 21 130,20
20/09/2023 2 10 63,00 4 80 511,20
21/09/2023 4 100 618,00 1 50 315,00
22/09/2023 7 239 1 465,07 1 1 6,28
25/09/2023 4 110 684,20 2 50 313,00
26/09/2023 9 430 2 558,50 2 50 314,50
27/09/2023 12 791 4 445,42 5 122 744,20
28/09/2023 12 710 3 564,20 2 200 1 008,00
29/09/2023 2 50 252,00 5 300 1 554,00
02/10/2023 3 130 661,70 – – –
03/10/2023 18 540 2 624,40 11 400 2 000,00
04/10/2023 3 130 666,90 3 110 569,80
05/10/2023 3 234 1 404,00 18 588 3 580,92
06/10/2023 2 50 313,00 3 60 379,80
09/10/2023 9 190 1 155,20 – – –
10/10/2023 5 105 628,95 2 30 183,00
11/10/2023 9 167 993,65 3 49 300,37
12/10/2023 1 1 5,82 4 51 306,00
13/10/2023 6 73 427,78 2 23 140,30
16/10/2023 1 99 588,06 1 48 288,00
17/10/2023 2 11 66,00 1 1 5,98
18/10/2023 3 35 211,75 3 39 239,85
19/10/2023 6 139 849,29 3 80 498,40
20/10/2023 3 8 48,72 2 21 129,99
23/10/2023 4 67 414,73 1 20 124,00
24/10/2023 5 74 454,36 2 21 130,20
25/10/2023 2 18 111,60 1 1 6,22
26/10/2023 – – – 8 339 2 278,08
27/10/2023 5 140 974,40 4 49 348,88
30/10/2023 6 90 632,70 1 21 151,20
31/10/2023 2 40 286,40 12 354 2 708,10
01/11/2023 4 400 3 164,00 10 338 2 879,76
02/11/2023 19 1 720 13 553,60 – – –
03/11/2023 22 1 108 8 110,56 – – –
06/11/2023 5 77 599,83 5 82 655,18
07/11/2023 5 95 787,55 8 140 1 164,80
08/11/2023 7 125 1 028,75 1 20 166,00
09/11/2023 10 207 1 674,63 2 6 49,80
10/11/2023 20 216 1 736,64 1 1 8,06
13/11/2023 11 117 932,49 – – –
14/11/2023 4 69 539,58 4 48 379,68
15/11/2023 11 270 2 060,10 4 140 1 104,60
16/11/2023 5 121 917,18 4 75 574,50
17/11/2023 3 90 695,70 – – –
20/11/2023 10 484 3 562,24 4 61 461,16
21/11/2023 13 303 2 172,51 3 92 678,96
22/11/2023 4 63 451,71 3 43 313,90
23/11/2023 4 93 675,18 – – –
24/11/2023 4 65 467,35 – – –
27/11/2023 8 161 1 122,17 1 1 7,14
28/11/2023 6 140 952,00 3 110 767,80
29/11/2023 3 200 1 380,00 1 1 6,96
30/11/2023 5 140 945,00 2 90 610,20
01/12/2023 21 389 2 594,63 13 415 3 037,80
04/12/2023 2 100 685,00 5 147 1 043,70
05/12/2023 – – – 2 65 455,00
06/12/2023 1 17 118,32 3 75 525,00
07/12/2023 11 349 2 348,77 3 90 618,30
08/12/2023 15 251 1 641,54 4 61 405,65
11/12/2023 7 154 1 057,98 22 1 083 7 873,41
12/12/2023 4 48 340,80 9 300 2 145,00
13/12/2023 13 238 1 635,06 – – –
14/12/2023 4 60 403,20 3 60 409,80
15/12/2023 9 190 1 271,10 11 300 2 055,00
18/12/2023 4 20 135,60 2 15 102,30
19/12/2023 5 71 484,22 5 21 143,43
20/12/2023 5 60 418,20 10 225 1 579,50
21/12/2023 10 92 623,76 4 81 568,62
22/12/2023 10 137 946,67 15 261 1 827,00
27/12/2023 4 75 536,25 8 210 1 507,80
28/12/2023 3 35 250,25 4 80 583,20
29/12/2023 11 314 2 179,16 8 165 1 166,55

About 91桃色视频

91桃色视频, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 91桃色视频 has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, 驳耻迟笔谤颈苍迟庐, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 91桃色视频 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 91桃色视频 is listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company鈥檚 control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 鈥渢arget,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁im,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渨ill,鈥� 鈥渃an have,鈥� 鈥渓ikely,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渃ould鈥� and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company鈥檚 control that could cause the Company鈥檚 actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at 91桃色视频. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson鈥檚 Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company鈥檚 scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of 齿别谤惫测迟别驳庐 in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

CEO and co-founder

Herv茅 Affagard

Herv茅 Affagard is the CEO and co-founder of 91桃色视频. For the past 15 years, Herv茅 has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Herv茅 co-founded the company alongside Dr. Jo毛l Dor茅, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Herv茅 has led 91桃色视频鈥檚 development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Herv茅 has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA